Study Overview

This study aims to genetically elucidate the mechanisms by which insulin regulates blood glucose and the underlying causes of insulin resistance and diabetes. By collecting and comparatively analyzing blood, plasma, DNA, and RNA samples, we seek to clarify disease pathogenesis.

Clinical Design and Population

Initiated in February 1976, the project is currently recruiting adult participants. Approximately 100–150 mL of blood will be drawn per subject, with the option to collect up to an additional 350 mL if needed, and skin tissue biopsies may also be performed. A subset of participants will undergo testing after a 72‑hour fast to precisely assess metabolic state changes.

Current Treatment Landscape and Differentiation

Current diabetes management relies on insulin administration and glucose‑lowering agents, yet understanding of the fundamental genetic drivers remains limited. This research directly investigates insulin‑cell binding mechanisms and genetic variants, enabling the discovery of novel biomarkers that differentiate from existing therapies. Identification of genetic targets will provide a critical foundation for next‑generation therapeutic development.

Potential Impact

A large‑scale genetic database can be leveraged by pharmaceutical and biotech companies to prioritize drug candidates. Moreover, a precise understanding of insulin‑resistance mechanisms will facilitate personalized treatment strategies, markedly improving therapeutic efficiency for patients. Findings are expected to influence not only peer‑reviewed publications but also governmental policies and health guidelines.